Stocks and Investing Stocks and Investing
Mon, April 19, 2021

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $253 on, Apr 19th, 2021


Published on 2024-10-27 16:17:28 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $251 to $253 on, Apr 19th, 2021.

Matthew has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $265 on, Friday, April 16th, 2021
  • Brian Skorney of "Baird" Upgraded from Hold to Buy and Increased Target to $252 on, Tuesday, February 23rd, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021
Contributing Sources